Esperion Therapeutics, Inc. 8-K

What Happened

• Esperion Therapeutics, Inc. announced on March 2–3, 2026 that it entered into an Agreement and Plan of Merger to acquire Corstasis Therapeutics, Inc. through a merger in which Corstasis will become a wholly‑owned subsidiary of Esperion.
• The deal calls for $75,000,000 in cash upfront (subject to customary adjustments) and up to $180,000,000 in contingent milestone payments tied to regulatory approvals or commercial sales; additional royalty or license‑revenue‑derived payments may also be payable.

Key Details

• Upfront cash: $75,000,000 (subject to customary adjustments and a post‑closing purchase price adjustment).
• Contingent consideration: up to $180,000,000 for regulatory/commercial milestones, plus potential royalty/licensing‑revenue payments on future product sales.
• Corporate mechanics: Esperion’s wholly owned Merger Sub will merge into Corstasis; Corstasis common stock, options and RSUs will be cancelled and converted into the right to receive cash (pro rata share of the consideration), net of withholding and option exercise price.
• Closing conditions and timing: customary conditions apply; either party may terminate in certain circumstances and the agreement may be terminated if the transaction is not completed by May 1, 2026.
• Disclosure/Investor outreach: Esperion and Corstasis issued a joint press release and held an investor call on March 3, 2026; an investor presentation was provided.

Why It Matters

• This acquisition expands Esperion’s pipeline and commercial prospects (the companies highlighted potential benefits related to Enbumyst and a congestive heart failure opportunity in their disclosures). For investors, the deal shifts upfront cash ($75M) onto Esperion’s balance sheet use and adds contingent future payment obligations (up to $180M) dependent on milestone achievement.
• Key investor considerations include integration risk, the contingent nature of much of the deal value, required closing conditions (and the May 1, 2026 outside date), and the cash impact at closing versus future payouts tied to Corstasis’s product outcomes.